Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer

PURPOSE: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1000-fold lower error rate than conventional sequencing. EXPERIMENT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Parsons, Heather A., Rhoades, Justin, Reed, Sarah C., Gydush, Gregory, Ram, Priyanka, Exman, Pedro, Xiong, Kan, Lo, Christopher C., Li, Tianyu, Fleharty, Mark, Kirkner, Greg, Rotem, Denisse, Cohen, Ofir, Yu, Fangyan, Fitarelli-Kiehl, Mariana, Leong, Ka Wai, Hughes, Melissa, Rosenberg, Shoshana M., Collins, Laura C., Miller, Kathy D., Blumenstiel, Brendan, Trippa, Lorenzo, Cibulskis, Carrie, Neuberg, Donna, DeFelice, Matthew, Freeman, Samuel S., Lennon, Niall J., Wagle, Nikhil, Ha, Gavin, Stover, Daniel G., Choudhury, Atish D., Getz, Gad, Winer, Eric P., Meyerson, Matthew, Lin, Nancy U., Krop, Ian E., Love, J. Christopher, Makrigiorgos, G. Mike, Partridge, Ann, Mayer, Erica, Golub, Todd R., Adalsteinsson, Viktor A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7654718/
https://ncbi.nlm.nih.gov/pubmed/32170028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados